What changed in Becton, Dickinson And Company's latest annual report
In the year ended 30 Sep 2025, Becton, Dickinson And Company's revenue rose 8.2% to USD 21.84bn, from USD 20.18bn; net income fell 1.6% to USD 1.68bn, from USD 1.71bn; cash and cash equivalents fell 62.7% to USD 641.00m, from USD 1.72bn.
Year ended 30 Sep 2025. Source: 10-K filed 25 Nov 2025, read it on SEC EDGAR.
USD 20.18bn to USD 21.84bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 20.18bn | 21.84bn | Up 8.2% |
| Net income | 1.71bn | 1.68bn | Down 1.6% |
| Total assets | 57.29bn | 55.33bn | Down 3.4% |
| Long-term debt | 17.94bn | 17.62bn | Down 1.8% |
| Cash and cash equivalents | 1.72bn | 641.00m | Down 62.7% |
| Shareholders' equity | 25.89bn | 25.39bn | Down 1.9% |
Questions people ask
Did Becton, Dickinson And Company's revenue grow last year?
Revenue grew 8.2%, from USD 20.18bn to USD 21.84bn in the year ended 30 Sep 2025.
Is Becton, Dickinson And Company profitable?
Yes. Net income was USD 1.68bn in the year ended 30 Sep 2025. The year before: USD 1.71bn.
How much cash and debt does Becton, Dickinson And Company have?
At its latest year end (30 Sep 2025), Becton, Dickinson And Company reported cash and cash equivalents of USD 641.00m and long-term debt of USD 17.62bn.
Where do these numbers come from?
From Becton, Dickinson And Company's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Becton, Dickinson And Company?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%
- Solventum CorporationNet income up 224.8%